Inozyme Pharma Stock Forum

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Inozyme Pharma (INZY) announced positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. The trial demonstrated that INZ-701 significantly increased plasma pyrophosphate (PPi) levels in patients, with levels rising into the normal range by week 3 of the four-week dosing schedule. The drug was well-...

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Inozyme Pharma (Nasdaq: INZY) has published preclinical data in the journal Cells, supporting the potential of INZ-701, their lead ENPP1 enzyme replacement therapy (ERT) candidate, to treat a broad range of rare diseases affecting bone health and blood vessel function. The study demonstrates IN...

$Inozyme Pharma (INZY.US)$
NEWS
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS)...

$SPDR S&P Biotech ETF (XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

$Inozyme Pharma (INZY.US)$ Never Buy 👉 Suspend Short Trap Delete Now 👉💰